YM-53601, a novel squalene synthase inhibitor, suppresses lipogenic biosynthesis and lipid secretion in rodents-Reference-Cited by-同舟云学术

YM-53601, a novel squalene synthase inhibitor, suppresses lipogenic biosynthesis and lipid secretion in rodents

Published:2003-05 Issue:1 Volume:139 Page:140-146
ISSN:0007-1188
Container-title:British Journal of Pharmacology
language:en
Short-container-title:

Author:

Ugawa Tohru,Kakuta Hirotoshi,Moritani Hiroshi,Inagaki Osamu,Shikama Hisataka

Publisher

Wiley

Subject

Pharmacology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1038/sj.bjp.0705229/fullpdf

Reference28 articles.

1. RPR 107393, a potent squalene synthase inhibitor and orally effective cholesterol-lowering agent: comparison with inhibitors of HMG-CoA reductase;AMIN;J. Pharmacol. Exp. Ther.,1997

2. Efficacy and safety of a new HMG-CoA reductase inhibitor, atorvastatin, in patients with hypertriglyceridemia;BAKKER-ARKEMA;JAMA,1996

3. Enhancement of fatty acid and cholesterol synthesis accompanied by enhanced biliary but not very-low-density lipoprotein lipid secretion following sustained pravastatin blockade of hydroxymethyl glutaryl coenzyme A reductase in rat liver;CARRELLA;Metabolism,1999

4. Evidence that triglycerides are an independent coronary heart disease risk factor;CULLEN;Am. J. Cardiol.,2000

5. Inhibition of cholesterol synthesis in vitro and in vivo by ML-236A and ML-236B, competitive inhibitors of 3-hydroxy-3-methylglutaryl-Coenzyme A reductase;ENDO;Eur. J. Biochem.,1977

Cited by 23 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Fine‐Tuning of Cholesterol Homeostasis Controls Erythroid Differentiation;Advanced Science;2021-11-05

2. Small Regulators of;Ferroptosis: Mechanism and Diseases;2021

3. Genome-scale integration of transcriptome and metabolome unveils squalene synthase and dihydrofolate reductase as targets against AML cells resistant to chemotherapy;COMPUT STRUCT BIOTEC;2021

4. Genome-scale integration of transcriptome and metabolome unveils squalene synthase and dihydrofolate reductase as targets against AML cells resistant to chemotherapy;Computational and Structural Biotechnology Journal;2021

5. Bavachinin inhibits cholesterol synthesis enzyme FDFT1 expression via AKT/mTOR/SREBP-2 pathway;International Immunopharmacology;2020-11